The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InTheravance Biopharma (TBPH) shares plummeted 26% in morning trading following news that its Phase 3 CYPRESS study for ampreloxetine failed to meet its primary endpoint. The trial was specifically evaluating the drug's efficacy in patients with multiple system atrophy (MSA), a rare neurological condition. In response to the clinical setback, the company has engaged Lazard to explore a potential sale of the business as part of an accelerated strategic review. Concurrent with these efforts, Theravance is implementing a major restructuring plan aimed at reducing its cost base by 60%, or approximately $70 million annually. The company will now pivot its focus toward its commercial product YUPELRI to drive cash flow while maintaining a projected cash balance of $400 million by Q1 2026. This strategic shift highlights the company's urgent need to preserve capital and maximize the value of its remaining assets after losing a key growth catalyst.